Boston Scientific wins CE mark for mapping system; Globus launches spinal spacer;

Medical Device News

@FierceMedDev: Boston Scientific: Watchman beats warfarin in follow-up. Article | Follow @FierceMedDev

@MarkHFierce: Nanostim's leadless pacer has had some success in early human trials. Future buyer St. Jude Medical must be pleased. Story | Follow @MarkHFierce

 @DamianFierce: St. Jude: Independent analysis says Durata leads are safe, reliable. Report | Follow @DamianFierce

> Boston Scientific ($BSX) won a CE mark for Rhythmia, a 3-D mapping system used in electrophysiology procedures. Story

> Globus Medical ($GMED) has launched its Fortify I corpectomy spacer for spinal surgery. News

> Rosetta Genomics ($ROSG) has settled its spat with Sanra Laboratories, receiving a $625,000 payment. More

> Bacterin ($BONE) posted $8.6 million in first-quarter revenue, a 6% jump, and the company narrowed its losses by 3% to $1.2 million. Results

> Life Care Medical Devices has expanded into Europe, opening a Dublin outpost to base its continental operations. Item

> Critical Diagnostics is touting a new study establishing the ST2 biomarker, used in the company's Presage ST2 Assay, as the most potent predictor of heart failure rehospitalization. Release

Biotech News

@FierceBiotech: Novartis' Ilaris approved by FDA to treat active systemic juvenile idiopathic arthritis. Release | Follow @FierceBiotech

@JohnCFierce: Looks like Takeda management maybe in for more changes.The numbers are awful. Report | Follow @JohnCFierce

@RyanMFierce: My story on how industry legend Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups. Article | Follow @RyanMFierce

> Pain Therapeutics, Durect shares nosedive on haziness for Pfizer's Remoxy. Report

> Eli Lilly jettisons cancer contender after another Phase III failure. Story

> Biotech VC firm Frazier Healthcare closes in on $300M fund. More

> Deborah Dunsire exits as Takeda cuts CEO role in Millennium shakeup. News

Pharma News

@FiercePharma: WSJ: J&J's multibillion-$$ Risperdal settlement snags on breast side effects. $JNJ worried a/b civil suits. Article | Follow @FiercePharma

@EricPFierce: Pharma M&A way up in Q1 2013 compared to a year ago. Value up more than 500%. Feature | Follow @EricPFierce

> Motherhood at center of Merck gender bias suit. Article

> Amgen forges Chinese JV for Vectibix. Story

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.